Panacea Journal of Medical Sciences

---

A retrospective study on management of bell's palsy in a tertiary care hospital

Full Text PDF Share on Facebook Share on Twitter

---

Original Article

Author Details : Dhanyan Harshidan, P.K Purushothaman*, Priyangha Elangovan

Volume : 11, Issue : 2, Year : 2021

Article Page : 173-176

https://10.18231/j.pjms.2021.038

Suggest article by email

---

Abstract

IIntroduction: Bell’s palsy is the most common facial nerve disorder. The clinical symptoms of Bell’s palsy include facial muscle paralysis, difficulty in eating, drinking and talking. Bell’s palsy management is still controversial. Many patients recover spontaneously; some require medicines like corticosteroids, antiviral drugs and other managements.
Aim: To study the effectiveness of Bell’s palsy management that has been followed in our institution. 
Materials and Methods: This analysis had carried out from June 2016 to June 2019at SRM Medical College Hospital and Research Institute, Chennai. Total of 30 patients with Bell’s palsy who had admitted in the Department of Otorhinolaryngology had enrolled in this study. All the patients underwent thorough clinical examination and laboratory investigation, and the results were statistically analyzed and discussed. 
Results: Out of 30 patients, 16(53%) patients were males, and 14(47%) patients were females. 53.3% of patients had onset of symptoms after 48 hours. There was a statistical significant improvement in House-Brackman scale on 6 months follow-up.
Conclusion: The therapeutic measures for Bell’s palsy if initiated within 72 hours of onset aids in bringing better outcome and improves the quality of life in patients.
 

Keywords : Bell's palsy, House­Brackman scale, Corticosteroids, Paralysis

How to cite : Harshidan D, Purushothaman P, Elangovan P, A retrospective study on management of bell's palsy in a tertiary care hospital. Panacea J Med Sci 2021;11(2):173-176

Copyright © 2021 by author(s) and Panacea J Med Sci. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)